Hanmi Pharm

Hanmi Pharm, established in 1973, is a prominent biopharmaceutical entity headquartered in Seoul, South Korea. The company maintains a rigorous focus on research and development, prioritizing the discovery and commercialization of innovative therapeutic solutions. By leveraging advanced scientific methodologies, Hanmi Pharm addresses significant unmet medical needs within the global healthcare sector. The organization operates with a core philosophy centered on technology-driven pharmaceutical innovation, aiming to enhance human health outcomes through consistent value creation and strategic R&D investments.

The company maintains a robust operational footprint with a workforce of 1,000-5,000 employees. Listed on the Korea Exchange under the ticker KRX: 128940, Hanmi Pharm demonstrates significant market presence in the pharmaceutical industry. Its operational model integrates comprehensive drug development pipelines, ranging from initial discovery to final commercialization. The firm specializes in developing novel medicines, including advanced anticancer drug candidates, which are designed to meet evolving clinical requirements. This technical infrastructure supports its mission to remain at the forefront of the biopharmaceutical landscape.

Hanmi Pharm continues to expand its influence across the Asian market and beyond, driven by its commitment to scientific excellence. The company’s dedication to R&D is reflected in its diverse product portfolio and ongoing clinical projects. Meet Hanmi Pharm's team to learn about the leadership and scientific experts driving these initiatives. By focusing on high-impact pharmaceutical research, the organization ensures its competitive positioning in the global healthcare market. Hanmi Pharm remains a key player in the development of next-generation medical treatments, consistently pushing the boundaries of pharmaceutical science to improve patient careView more...